Help us find the people building the technology behind better sleep and healthier lives.

At Resmed, our work helps millions of people living with sleep apnoea, COPD and other chronic conditions sleep better and live healthier, longer lives. Behind that impact are Product and Technology teams solving complex problems across hardware, software, data, AI and digital health. As Talent Acquisition Lead, North America, you will help find, engage and hire the people who make that work possible.

This is a senior, hands-on recruiting leadership role based in San Diego, working hybrid with two days each week in our San Diego corporate office. You will lead recruitment delivery for critical Product and Technology hiring across North America, personally manage complex senior searches, advise leaders on talent strategy and develop a small team of TA Partners across the USA and Canada. The position is full-time and permanent.

What You'll Do

Lead recruitment delivery for Product and Technology hiring across North America, with priority focus on San Diego and Atlanta, including Resmed's Brightree business.
Act as principal recruiter for complex searches, from intake and market mapping through to assessment and offer strategy, with a consistent focus on candidate engagement.
Manage, coach and develop a small team of TA Partners across the USA and Canada, lifting standards while keeping delivery practical and commercially focused.
Advise senior leaders and People Business Partners on talent markets, search strategy, pipeline health, assessment quality and hiring risk.
Strengthen regional recruiting practice across briefing, sourcing, stakeholder engagement, candidate experience and evidence-based decision making.
Lead monthly pipeline reviews with clear actions, strong market coverage and visible attention to diversity, ageing roles and delivery risks.

What You Bring

10+ years of product and technology recruitment experience, with a strong record delivering senior specialist and leadership searches across product and emerging tech domains, particularly senior Product Management and Product Strategy roles.
Deep North American talent acquisition delivery experience, with strong knowledge of the USA, US West Coast and California Product Management talent markets.
Demonstrable capability in partnering with senior business leaders and People Business Partners to shape hiring strategies and resolve delivery risks.
3+ years' people management and team development experience, with the ability to guide, support and develop recruiters across a multi-location North American environment.
Demonstrated experience in building TA delivery capability and hiring quality, with the independence to serve as a senior advisor to stakeholders across multiple locations in North America
Strong executive search and strategic sourcing skills, including market mapping, passive candidate engagement, pipeline governance and evidence-based search planning.
Confidence in using data, recruitment analytics and AI to monitor performance, identify trends and provide value-adding insights and enhancements for TA leadership and People Business Partners.

What Sets You Apart

Sharp judgement: You know the market and the skills, providing talent intelligence and advice to help leaders make better hiring decisions.
Kind, yet direct: You give honest advice that maintains trust with leaders, recruiters, and candidates.
Generous with your craft: You listen intently, share what works and help other recruiters build stronger habits, not just busier calendars.
Curious and resourceful: You look past the obvious playbook, testing new sourcing channels and approaches to crack hard-to-fill roles.
Stay close to the detail: You know when a search is healthy, when it is drifting and when a leader needs a sharper plan.
Master the balance: You keep momentum across markets and time zones without losing care for people.

Why Join Resmed

Resmed sits at the intersection of medical devices, software, data and connected care. For a senior TA professional, this role offers the kind of work that has real substance: complex searches, senior stakeholder partnerships, a regional leadership remit and hiring portfolios tied to products that genuinely improve people's lives.

You will join a global Talent Acquisition team with executive support for talent as a business priority. You will work alongside highly capable yet grounded colleagues who care about quality, pace, and the human side of hiring. We offer competitive total compensation, flexible working and a culture that takes professional development seriously. If you want to lead meaningful senior hiring, develop recruiters and help build the future of sleep health, we would like to hear from you.

Benefits and Compensation

At Resmed, we're shaping the future by investing in our people through competitive pay, flexible work arrangements, and programs that support personal and professional growth.

Benefits (employees regularly scheduled to work 30+ hours per week) include:

Medical, dental, vision, life, AD&D, and disability insurance
HSA, FSA, commuter benefits, and sleep care management
401(k), ESPP, EAP, and tuition assistance
Flexible Time off (FTO) for salaried employees
11 paid holidays plus 3 floating holidays
Up to 14 weeks primary caregiver leave or 2 weeks secondary caregiver leave

Compensation: Compensation is based on factors including geographic location, qualifications, experience, skills, and internal equity.

Pay Range: $118,000 - $178,000 USD Annual.

This role may be eligible for participation in an Annual Bonus Plan subject to applicable plan terms and eligibility.

Resmed generally does not hire at or near the top of the pay range. For remote positions outside the U.S., compensation is determined based on geographic location, qualifications, experience, and skills.

Joining us is more than saying “yes” to making the world a healthier place. It’s discovering a career that’s challenging, supportive and inspiring. Where a culture driven by excellence helps you not only meet your goals, but also create new ones. We focus on creating a diverse and inclusive culture, encouraging individual expression in the workplace and thrive on the innovative ideas this generates. If this sounds like the workplace for you, apply now! We commit to respond to every applicant.

About the company

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify's Take

What believers are saying

September 2026 guidance shows 5%-7% revenue growth and 12%-14% core EPS growth.
MatrixCare closed September 1, 2026, freeing capital for higher-margin core businesses.
ResMed's connected network and Oura partnership expand diagnosis and PAP adoption funnels.

What critics are saying

Astral no-new-sales in fiscal 2027 removes $75 million revenue and damages trust.
KPMG exit and PwC onboarding increase reporting disruption risk before the next 10-Q.
Philips Respironics' U.S. return in 2027 can compress pricing and share quickly.

What makes Resmed unique

ResMed's cloud-connected AirSense platform locks in recurring resupply and adherence data.
Noctrix acquisition broadens ResMed beyond apnea into restless legs syndrome treatments.
MatrixCare sale and core-device focus sharpen execution around sleep, breathing, and home care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Parental Leave
401(k) Retirement Plan
Employee Assistance Program (EAP)

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Yahoo Finance

Oct 23rd, 2026

ResMed launches AirTouch F40 mask in US, but analysts see only an incremental boost

ResMed has launched its AirTouch F40 CPAP mask in the US. The fabric-cushioned design connects to the company's myAir and AirView platforms and aims to improve comfort, adherence and fitting for obstructive sleep apnea patients. Existing AirFit F40 users can switch to the new ComfiSoft fabric cushion without a full refit. This could lift resupply activity and keep patients within ResMed's connected ecosystem. The launch looks incremental. Supply chain costs and the Astral ventilator remediation remain the main near-term risks, with a headwind expected in FY2027. From July to September 2026, ResMed retired 972,000 shares for $200 million. Analysts' narrative projects $6.6 billion in revenue and $1.9 billion in earnings by 2029.

GlobeNewswire

Oct 19th, 2026

Resmed launches AirTouch(TM) F40 full face fabric CPAP mask in the U.S.

Resmed launches AirTouch(TM) F40 full face fabric CPAP mask in the U.S. Latest addition to Resmed's growing fabric mask portfolio combines a soft, breathable fabric cushion with a minimalist design for greater comfort and choice. October 19, 2026 08:00 ET | Source: Resmed, Inc. SAN DIEGO, Oct. 19, 2026 (GLOBE NEWSWIRE) - Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced the U.S. launch of AirTouch F40, the newest addition to its growing portfolio of fabric continuous positive airway pressure (CPAP) masks. Designed for people with obstructive sleep apnea (OSA) to provide greater comfort and choice in therapy[1], the AirTouch F40 helps address key factors that can influence long-term adherence. OSA is a growing health challenge, affecting more than one billion people worldwide.[2] In the U.S., an estimated 61 million people have OSA, a number projected to rise to nearly 77 million by 2050.[3] CPAP therapy remains the gold standard treatment for OSA[4], and for those on CPAP, mask comfort and fit can play an important role in how people stay engaged with therapy over time. AirTouch F40 brings Resmed's proprietary ComfiSoft(TM) fabric cushion to a minimalist design that is intended to adapt to a person's face as they move throughout the night. Because comfort preferences vary from person to person, expanding mask choice helps give people another option to meet their individual needs. The mask's wide fit range and intuitive design are also intended to make it easier for healthcare providers to help patients find a comfortable fit and support them throughout therapy. AirTouch F40 builds on Resmed's growing portfolio of fabric-based mask technology and reflects the company's commitment to delivering more personalized experiences that support patients throughout their therapy experience. Resmed has seen encouraging outcomes across its fabric mask portfolio, including a 6% increase in 90-day compliance among users of a fabric-cushioned mask compared with users of a silicone-cushioned mask.[5] "AirTouch F40 is one example of how we're continuing to redefine what's possible to create more comfortable and personalized therapy experiences," said Justin Leong, Chief Product Officer at Resmed. "By building on the success of AirFit F40(TM) and introducing a new fabric option, we're giving people greater flexibility to choose the mask that works best for them. That's the kind of innovation that can help more people start and stay on CPAP therapy." Key features of AirTouch F40 include: * Designed to fit and move with the user: AirTouch F40 is designed to fit 96% of people[6] with a minimalist design that adapts to the face as people move throughout the night. * Brings fabric comfort to the full-face experience: The ComfiSoft fabric cushion features soft, breathable, and moisture-wicking fabric[7] designed for comfort against the skin. * A familiar platform for existing AirFit F40 users: The interchangeable cushion allows current AirFit F40 users to try the fabric cushion without changing mask systems or being resized or refitted. Connected support throughout therapy AirTouch F40 is part of Resmed's connected sleep health platform, bringing together devices, digital tools and provider support to create a more connected therapy experience and help people stay engaged over time. Through myAir(TM), Resmed's patient engagement app, people can track their therapy progress, access personalized guidance and receive ongoing support throughout their therapy experience. This includes upcoming features such as Equipment Care, a tool that is designed to encourage patients to take action and stay engaged in managing their CPAP equipment. Healthcare providers can use AirView(TM), Resmed's remote monitoring platform, to view therapy insights and support patients between appointments. When used alongside AirView, myAir has been shown to improve therapy compliance from 70% to 87%.[8] AirTouch F40 will be available in the U.S. beginning October 28, 2026. For more information, visit https://www.resmed.com/en-us/health-professionals/campaigns/airtouch-f40/ About Resmed Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed. For Investors [1] Resmed external crossover study comparing AirTouch F40 mask against other Resmed and third-party masks. n=36. Data on file, ID: A5768170. [2] Benjafield AV, et al. Lancet Respir Med. 2019 Aug; 7(8):687-698. [3] Boers E, et al. Lancet Respir Med. 2025;13(12):1078-1086. [4] Patil SP et al. J Clin Sleep Med. 2019 Feb 15;15(2):301-334. [5] Resmed analysis of 90-day PAP compliance among U.S. patients using AirView(TM) and myAir(TM), comparing AirTouch(TM) N30i and AirFit(TM) N30i. Data on file, ID: A5707362. [6] Internal Resmed analysis of projected cushion fit per region. Data on file, ID: A5756043. [7] Resmed internal testing of the moisture-wicking properties of fabric. Data on file, ID: A5636924. [8] Malhotra et al., CHEST. 2018; 153(4): 843-850.

HEM News

Oct 19th, 2026

Resmed invests in Eight Sleep and links myAir data to its smart mattress app

Eight Sleep and Resmed have formed a partnership to help people in the US and Australia better understand their sleep health. Resmed has also invested in Eight Sleep; the source gives no amount. Users of a Resmed PAP device with the myAir app and an Eight Sleep Pod can now connect their myAir insights to the Eight Sleep app. With the user's permission, the data appears alongside Eight Sleep metrics, so members can track it over time. The integration is live in both countries. The companies plan to expand to more markets. "This collaboration allows Eight Sleep members who use a Resmed PAP device with the myAir app to gain broader insights into their sleep health," said Matteo Franceschetti, co-founder and chief executive officer of Eight Sleep.

Yahoo Finance

Sep 19th, 2026

ResMed achieves 9% revenue growth to $1.5B amid sleep apnea demand, but fiscal 2027 guidance misses expectations

ResMed Inc. (NYSE: RMD) is positioned to benefit from growing awareness and penetration in the global obstructive sleep apnea treatment market, backed by its robust product portfolio. The portfolio includes CPAP and APAP machines, led by the AirSense platform, along with masks and accessories. In the fourth quarter of fiscal 2026, ResMed's revenue increased 9% year over year to $1.5 billion. Americas device revenue rose 6%, whilst total Americas Sleep and Breathing Health revenue increased 8%. On 15 September, RBC Capital upgraded ResMed to Outperform, raising its price target to $262 from $244. However, the company faces competitive pressures, particularly from the potential return of Philips Respironics to the US market. ResMed issued 2027 revenue guidance of $5.75 billion to $5.85 billion, below analysts' expectations of $5.92 billion.

Yahoo Finance

Sep 14th, 2026

ResMed falls 20.5% over 52 weeks despite Q4 revenue beat amid margin compression

ResMed, a San Diego-based developer of medical devices for respiratory disorders, has underperformed the healthcare sector over the past year. The company, valued at $31.5 billion, has declined 20.5% over 52 weeks, whilst the State Street Healthcare Select Sector SPDR ETF rose 21% during the same period. The stock fell 5.1% on 7 August following its Q4 earnings release. Whilst revenue increased 8.6% year-over-year and adjusted earnings per share of $2.95 beat forecasts, operating margin compressed to 30.7% from 33.7% the previous year. Management attributed the margin decline to higher R&D and supply chain costs amid inflation. Despite recent underperformance, the stock has gained 13.5% over the past three months. Wall Street analysts maintain a "moderate buy" rating, with a mean price target suggesting 9.1% upside potential.

Resmed

Lead Talent Acquisition - Product & Technology

About the job

About the company

Get referred to Resmed

Simplify's Take

What believers are saying

What critics are saying

What makes Resmed unique

Benefits

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth